Highest-materiality recent filing
WestGene receives upfront payment and milestone-based payments; Cartesian gains exclusive rights to WestGene's tLNP platform for in vivo CAR-T.
Cartesian secures up to $150M debt facility; CMO resigns; Phase 3 data expected Q1 2027
Secured up to $150M credit facility with K2 HealthVentures; initial $50M tranche funded at close on May 22, 2026.
Cartesian Q1 net loss $39.2M ($1.46/sh) vs $17.7M; cash $120.4M; pipeline advances
Net loss widened to $39.2M from $17.7M YoY; higher R&D spend on Phase 3 AURORA trial.
Cartesian Therapeutics reports FY2025 net loss of $130.3M; cash $126.9M funds into mid-2027
Net loss of $130.3M ($5.02 per basic share) compared to $77.4M ($4.48) in FY2024.
Cartesian updates Descartes-08 pipeline; IND accepted in myositis, pediatric trial initiated
Phase 3 AURORA trial for Descartes-08 in myasthenia gravis enrollment on track; data expected to support cash runway into mid-2027.
Cartesian Therapeutics appoints Adrian Bot to board; brings CAR T and RNA therapy expertise
Appointed Adrian Bot, M.D., Ph.D., as Class II director effective Dec 16, 2025; will serve on Science and Technology Committee.
Cartesian reports 100% LLDAS response in Phase 2 SLE; expands Descartes-08 into myositis
100% LLDAS response at Month 3 (n=3) in Phase 2 SLE trial; 2 of 3 achieved DORIS remission.
Cartesian Q3 net loss $35.9M; cash $145.1M; AURORA trial on track
Net loss of $35.9M ($1.38/share) vs $24.2M ($1.13/share) in Q3 2024.
Cartesian Therapeutics eliminates CSO role, terminates Dr. Christopher Jewell effective Nov 14, 2025
CSO position eliminated; Dr. Christopher Jewell terminated without cause effective November 14, 2025.
Cash, equivalents and restricted cash $162.1M as of June 30, 2025; expected to fund operations into mid-2027.
Cartesian reports Descartes-08 Phase 2b MG data: sustained 12-month benefit, Phase 3 on track
Average MG-ADL reduction of 4.8 points at Month 12; 83% maintained clinically meaningful response.
Cartesian Therapeutics FY2024 net loss $77.4M; cash $214.3M; Phase 3 MG trial on track
Net loss of $77.4M ($4.48 loss per share) vs $219.7M loss in FY2023; R&D expenses $45.1M.
Cartesian Therapeutics receives FDA SPA agreement for Phase 3 AURORA trial of Descartes-08 in MG
FDA agrees under Special Protocol Assessment that Phase 3 AURORA trial design can support future BLA for Descartes-08 in myasthenia gravis.
Descartes-08 showed 5.5-point average MG-ADL reduction at Month 4 (n=12); 33% reached minimum symptom expression at Month 6.
Cartesian Q3 net loss $(24.2)M; cash $220.9M; Phase 3 Descartes-08 in MG expected 1H2025
Cash and equivalents $220.9M as of Sep 30, 2024; runway expected into mid-2027.
Stockholders at Sept 20 special meeting approved issuance of common shares from Series B Preferred Stock conversion.
Cartesian reports positive Phase 2b MG data, Q2 net income $13.8M, $130M PIPE
Phase 2b trial of Descartes-08 in MG met primary endpoint: 71% (10/14) of treated patients vs 25% (3/12) placebo had ≥5-point MGC improvement at Month 3 (p=0.018).
Cartesian raises $130M via PIPE; Phase 2b MG trial meets primary endpoint, 71% responder rate
Raised ~$130M by selling 3.56M common shares and 2.94M Series B convertible preferred shares at $20 each.
Cartesian Therapeutics receives FDA RMAT designation for Descartes-08 in myasthenia gravis
FDA granted RMAT designation for Descartes-08, an autologous mRNA CAR-T therapy targeting BCMA for myasthenia gravis.
Cartesian Q1 2024 net loss $56.8M; cash $104.8M; MG Phase 2b data on track for mid-2024
Net loss $56.8M ($10.50/shr) vs $21.7M ($4.24/shr) Q1 2023; loss widened on higher G&A from merger.
Cartesian regains Nasdaq minimum bid price compliance; delisting risk removed
Received deficiency notice Jan 17, 2024 for bid price below $1.00 for 30 consecutive days.
Cartesian stockholders approve Series A conversion and 1-for-30 reverse split effective April 4
Stockholders approved issuance of common shares upon conversion of Series A Non-Voting Convertible Preferred Stock; automatic conversion set for April 8, 2024.
Astellas terminated the License and Development Agreement effective June 6, 2024, for Xork product candidate.
Cartesian Therapeutics FY2023 net loss $219.7M; cash runway into 2H26
Pro forma cash $118.3M as of Dec 31, 2023, expected to fund operations into 2H26.
Cartesian Therapeutics files financials for acquired Old Cartesian and pro forma
Old Cartesian net loss $6.5M in 2022, vs $3.6M in 2021; grant revenue $1.4M in 2022.
Cartesian Therapeutics receives Nasdaq notice of non-compliance with minimum bid price requirement
Nasdaq notified Cartesian on Jan 17, 2024 that its common stock closing bid price fell below $1.00 for 30 consecutive business days.
Cartesian reports positive 12-month Phase 2a data for Descartes-08 in MG; cash $118M
12-month follow-up: 5 of 7 Phase 2a MG patients maintained clinically meaningful improvements ~10 months after last infusion; autoantibodies durably reduced.
Selecta completes merger with Cartesian; renamed Cartesian Therapeutics, ticker RNAC
Merger closed Nov 13; Selecta issued 6.7M common shares and 384,931 Series A Preferred to Cartesian holders.
Selecta transitions SEL-212 manufacturing to Sobi; CMO goes part-time
Selecta granted Sobi exclusive license to manufacture ImmTOR for SEL-212; Sobi assumes all manufacturing and commercial supply.
Net loss of $11.4M ($0.07/share) vs net income of $8.6M ($0.06) in Q2 2022; collaboration revenue fell to $5.2M from $39.3M.
On May 22, 2026, Milos Miljkovic, M.D., the Company’s Chief Medical Officer, delivered a notice of resignation to the Company.
Dr. Kurtoglu’s employment with the Company will end effective May 1, 2025
On July 1, 2024, the Board of Directors (the “Board”) of the Company appointed Kemal Malik, MBBS as a Class II director, and fixed the size of the Board at nine directors.
As previously announced, on November 13, 2023, Cartesian Therapeutics, Inc. (the “Company”) appointed Christopher Jewell, Ph.D., age 43, to serve as the Company’s Chief Scientific Officer.
Under the terms of the Kurtoglu Employment Agreement, Dr. Kurtoglu will serve as the Company’s Chief Technology Officer, is entitled to receive an annual base salary of $440,000 and will be eligible for an annual performance bonus targeted at 40% of his annual base salary beginning in 2024.
On February 28, 2024, Aymeric Sallin, a member of the Board of Directors (the “Board”) of the Company, notified the Company of his resignation from the Board, effective immediately, to pursue other opportunities.
On November 21, 2023, Scott D. Myers, a member of the Board of Directors (the “Board”) of Cartesian Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board, effective immediately, to pursue other opportunities.
each of Peter Traber, Kei Kishimoto and Lloyd Johnston resigned as Chief Medical Officer, Chief Scientific Officer and Chief Operations Officer, respectively
the Board appointed Metin Kurtoglu as the Company’s Chief Operating Officer, Milos Miljkovic as the Company’s Chief Medical Officer, and Chris Jewell as the Company’s Chief Scientific Officer.
each of Peter Traber, Kei Kishimoto and Lloyd Johnston resigned as Chief Medical Officer, Chief Scientific Officer and Chief Operations Officer, respectively
each of Peter Traber, Kei Kishimoto and Lloyd Johnston resigned as Chief Medical Officer, Chief Scientific Officer and Chief Operations Officer, respectively
the Board appointed Metin Kurtoglu as the Company’s Chief Operating Officer, Milos Miljkovic as the Company’s Chief Medical Officer, and Chris Jewell as the Company’s Chief Scientific Officer.
Max materiality 0.85 · Median 0.60 · Most common event other_material